PT  - JOURNAL ARTICLE
AU  - IZUMI TAKEYOSHI
AU  - FUJIO MAKITA
AU  - YOSHIFUMI TANAHASHI
AU  - TADAHIRO YOKOMORI
AU  - SHIGERU IWAZAKI
AU  - YOSHIYUKI KAWASHIMA
AU  - KOTARO IWANAMI
AU  - TATSUYA YAMADA
AU  - SUSUMU KAWATE
AU  - KUNIHIRO HAMADA
AU  - YUTAKA SUNOSE
AU  - MIHO YOSHIDA
AU  - JUN HORIGUCHI
AU  - HIROSHI IESATO
AU  - MITSUNOBU KOBAYASHI
AU  - YASUO MORISHITA
TI  - A Combination Phase I Study of Weekly Paclitaxel and Doxifluridine in Advanced Gastric Cancer Patients
DP  - 2005 Mar 01
TA  - Anticancer Research
PG  - 1291--1296
VI  - 25
IP  - 2B
4099  - http://ar.iiarjournals.org/content/25/2B/1291.short
4100  - http://ar.iiarjournals.org/content/25/2B/1291.full
SO  - Anticancer Res2005 Mar 01; 25
AB  - Background: Preclinical studies have shown that paclitaxel and doxifluridine can act synergistically without overlapping toxicity for the treatment of advanced gastric cancer. The objectives of this study were to determine the maximum tolerated dose (MTD), the dose-limiting toxicity and the recommended Phase II dose for this drug combination. Patients and Methods: Patients with histologically confirmed gastric cancer were eligible for the study. The paclitaxel dose (days 1, 8, 15) was augmented with a fixed dose of doxifluridine (533 mg/m2, 5 days/week) on a 28-day cycle. Results: Eighteen patients were enrolled. The MTD was not reached until the highest dose level. One patient had Grade 3 myelosuppression. The responses of the 13 suitable patients included 1 complete response and 5 partial responses. Conclusion: Although the MTD level could not be definitively established, upon consideration of the lengthy administration time and the effectiveness, the recommended Phase II dose of paclitaxel was concluded to be 80 mg/m2 in combination with doxifluridine at 533 mg/m2. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved